

WEST

☐ [Generate Collection](#) [Print](#)

L14: Entry 7 of 57

File: USPT

Nov 5, 2002

DOCUMENT-IDENTIFIER: US 6475988 B1
TITLE: Methods to increase white blood cell survival after chemotherapy

Other Reference Publication (30):
Mutoh, et al., (1992), Urol. Int., "Local Control of Prostate Cancer by
Intraarterial Infusion Chemotherapy Facilitated by the Use of Angiotensin II", 48:
pp. 175-180.

WEST

Generate Collection

Print

L14: Entry 44 of 57

File: USPT

Jul 8, 1997

DOCUMENT-IDENTIFIER: US 5646042 A
TITLE: C-myb targeted ribozymes

Brief Summary Text (29):

In a preferred embodiment, the enzymatic RNA molecules cleave c-myb mRNA and inhibit smooth muscle cell proliferation. Such ribozymes are useful for the prevention of restenosis after coronary angioplasty. Ribozymes are added directly, or can be complexed with cationic lipids, packaged within liposomes, or otherwise delivered to smooth muscle cells. The RNA or RNA complexes can be locally administered to relevant tissues through the use of a catheter, infusion pump or stent, with or without their incorporation in biopolymers. The ribozymes, similarly delivered, also are useful for inhibiting proliferation of certain cancers associated with elevated levels of the c-myb oncogene, particularly leukemias, neuroblastomas, and lung, colon, and breast carcinomas. Using the methods described herein, other enzymatic RNA molecules that cleave c-myb, c-myc, oct-1, SRF, NF-.kappa.B, PDGF receptor, bFGF receptor, angiotensin II, and endothelium-derived relaxing factor and thereby inhibit smooth muscle cell proliferation and/or tumor cell proliferation may be derived and used as described above. Specific examples are provided below in the Tables.

WEST

Generate Collection

Print

L14: Entry 47 of 57

File: EPAB

Aug 12, 1999

PUB-NO: WO009940106A2
DOCUMENT-IDENTIFIER: WO 9940106 A2
TITLE: METHOD OF PROMOTING ERYTHROPOIESIS

PUBN-DATE: August 12, 1999

INVENTOR-INFORMATION:

NAME

RODGERS, KATHLEEN E
DIZEREGA, GERE

COUNTRY

ASSIGNEE-INFORMATION:

NAME

UNIV SOUTHERN CALIFORNIA

COUNTRY

US

APPL-NO: US09902648

APPL-DATE: February 8, 1999

PRIORITY-DATA: US07410698P (February 9, 1998), US11153598P (December 9, 1998)

INT-CL (IPC): C07 K 7/00

EUR-CL (EPC): A61K038/08; C12N005/00

ABSTRACT:

CHG DATE=19990902 STATUS=O>The present invention provides methods, compounds, pharmaceutical compositions, and kits for the augmentation of erythropoiesis by potentiating erythropoietin-induced differentiation with angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists as a therapeutic adjunct. The method is useful for the treatment of congenital or acquired aplastic or hypoplastic anemia associated with chronic renal failure, end-stage renal disease, renal transplantation, cancer, AIDS, chemotherapy, radiotherapy, bone marrow transplantation and chronic diseases.

WEST

Generate Collection

Print

L14: Entry 13 of 57

File: USPT

May 29, 2001

DOCUMENT-IDENTIFIER: US 6239109 B1
TITLE: Method of promoting erythropoiesis

Abstract Text (1):

The present invention provides methods, compounds, pharmaceutical compositions, and kits for the augmentation of erythropoiesis by potentiating erythropoietin-induced differentiation with angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II analogues, AII fragments or analogues thereof or AII AT.sub.2 type 2 receptor agonists as a therapeutic adjunct. The method is useful for the treatment of congenital or acquired aplastic or hypoplastic anemia associated with chronic renal failure, end-stage renal disease, renal transplantation, cancer, AIDS, chemotherapy, radiotherapy, bone marrow transplantation and chronic diseases.